Chordate Medical in the US – result from the migraine study is being presented

Tomorrow, Saturday, June 17th, coordinating study leader, Dr. Jan Hoffmann from King’s College in London, will present the primary parts of the final results from Chordate Medical’s pivotal clinical study PM007 at the American Headache Society Scientific Meeting. Chordate’s CEO, Anders Weilandt, is present in Austin, Texas.

“It’s very exciting, partly because it’s the first time the study’s final results are being presented at a conference, and also because it’s the first time the company is engaging in this type of activity in the USA,” says Anders Weilandt.

Chordate Medical CEO Anders Weilandt and Dr. Jan Hoffmann at American Headache Society Scientific Meeting in Austin, Texas.

In addition to Dr. Hoffmann’s lecture, Anders Weilandt has meetings with industry professionals and researchers over the weekend. The participants at the conference consist mainly of specialists in headache and migraine, with the majority being from the USA, but also including international visitors.

“The main focus is, of course, the presentation and capturing the expected interest it will generate. It’s also important to continue building networks within the industry represented at the conference and the associated exhibition.”

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy